



AESTIMO: GLOBAL FUNDS

A global catalogue of verified open international calls for non dilutive funding opportunities (public and private) that do not have single geography/national implementation restriction.

October 2019: Available funds summary

Indication	No.	Available (\$ Mn)	For companies (\$ Mn)
Cancer	39	92	5.6
Cardiac	4	13	0
Diabetes	10	35	2
Infectious disease	34	79	0
Inflammation	4	1.4	0.5
Kidney	8	19.5	0
Muscle	5	1	7
Neurological	86	192	4.4
Respiratory	9	12	3
Skin	9	11	2
Non indication specific	38	186	34
Bioengineering/tech	16	39	0
Global Clinical trials	3	3.6	0
Total*	265	684.5	58.5

The 'AESTIMO: Global Funds' catalogue, updated every month, is organised by indication (Cancer and Neurology further into sub indications), and technology, providing details on source, deadlines, values, focus, application links, and if 'companies' can also apply for non-dilutive funding.

For information on annual subscription to the complete and detailed monthly Global Funds, please contact Jonathan at jdando@aestimo.ie

About Aestimo:

Integrating late stage healthcare product launch, reimbursement and Health Technology Assessments with early stage innovation development in global markets, to generate and facilitate implementable strategies that maximise value for patients. We provide stakeholder tailored comprehensive packages that are adapted to enable development stage healthcare solution value creation throughout the lifecycle.

www.aestimo.ie

Aestimo Ltd © Use and distribution of the complete 'AESTIMO: GLOBAL FUNDS' subject to terms and conditions of the license agreement

**value does not include fellowships or single nation limited grants*